We are developing artificial intelligence models (patent-pending) that can screen and predict outcomes for COVID-19 within the first hour of presentation to emergency departments using only routine blood tests.
Our work is funded by some of the most prestigious organizations in science and technology, including the National Science Foundation and startup incubator YCombinator.
A former faculty member at the National Institutes of Health with over 20 peer-reviewed publications, Artur has built the flight controller software for the world's largest electric "flying car", helped Twitter scale its revenues from under $100M to over $2B, and presently leads the vision and AI at Biocogniv.
Prior to Biocogniv, Tanya was the COO/CTO at the cancer diagnostics company Genomic Expression. She has a PhD in Physical Chemistry from McGill and co-founded a life science instrumentation company (BioTrove) to commercialize the post-doctoral research she did at MIT.
Jed Batchelder is a Healthcare IT project manager with 15+ years of experience servicing health systems and software vendors. In addition to leading large-scale, cloud-based healthcare implementations, Jed has provided industry expertise to healthcare IT startups, and served as strategic advisor to hospital executives around the country.
Haley recently earned their B.S. in biomedical engineering from the University of Vermont. Their undergraduate research involved the use of AI to inform measures for predicting and preventing falls. This September, they will begin their PhD at UCLA as an NSF Graduate Research Fellow.
Adrian is a medical student at the University of Vermont Larner College of Medicine with an undergraduate degree in Biochemistry from Bucknell University. He is also a former lab manager at the Harvard Stem Cell Institute. Adrian is passionate about the applications of machine learning in diagnostic medicine.
Dr. Levine has been a clinical professor at Yale School of Medicine for over 40 years, and has authored and licensed over 100 patents in medical diagnostics, including several hematology devices like the Quantitative Buffer Coat, which has been commercialized to over $1B in sales.
Dr. Amin is Chair of the Department of Medicine and Executive Director of the Hospitalist Program at UC Irvine. He was a pioneer in establishing the field of hospital medicine, and the first hospitalist to become Chair of an academic Department of Medicine. Research interests range from hospital medicine and anticoagulation to AI and medical education.
As former COO of T2 Biosystems (IPO) and Boston Microfluidics, Sarah has spearheaded the clearance of several diagnostic devices with the FDA, and provides valuable guidance to Biocogniv's regulatory strategy.
Ed runs Larchmont Strategic Advisors and is an expert analyst of the legislative, regulatory, and economic forces that affect health care industry stakeholders. He has built a long track record of
successful management of reimbursement and other health care public policy advocacy programs.
John is a serial healthcare entrepreneur, having sold an FDA-compliant clinical trial software company to Phase Forward and then Oracle, and led product commercialization teams at various medical companies (JnJ, Abbott, Roche, Oracle, and IBM).
As the founder and CEO of Microstrain Inc., Steve built a technology startup from zero to over 70 employees through its successful exit to LORD Corporation, and now advises and invests in various companies in Vermont.
Dr. Weinberg is an Assistant Professor of Medicine at Cedars-Sinai, triple boarded in pulmonary, critical care, and internal medicine. He has a Master's degree from Cambridge University, and has co-authored several studies and clinical trials in critical care and pulmonary vascular medicine.
Dr. Tapson is a Professor of Medicine and Associate Director in the Pulmonary and Critical Care Division at Cedars-Sinai Medical Center. He has authored over 250 papers and has edited numerous books and chapters in pulmonology and critical care.
Dr. Plante is a physician scientist at the Larner College of Medicine at the University of Vermont, where he practices hospital and thrombosis medicine. He holds a masters degree in clinical epidemiology from John Hopkins, and researches cardiovascular disease, epidemiology, and mobile health technologies.
Dr. Siket is Associate Professor of Surgery and Neurological Sciences at the Larner College of Medicine at the University of Vermont, having taught medicine at Harvard and Brown. He practices emergency medicine and researches neurovascular diseases at UVM.